The Influence of CYP2C19 Genetic Polymorphism on the Pharmacokinetics/-Pharmacodynamics of Proton Pump Inhibitor-Containing Helicobacter pylori Treatments

被引：25

作者：

Serrano, Dolores ^{[1
]}

Torrado, Susana ^{[1
]}

Torrado-Santiago, Santiago ^{[1
]}

Gisbert, Javier P. ^{[2
]}

机构：

[1] Univ Complutense, Fac Farm, Dept Pharmaceut Technol, E-28040 Madrid, Spain

[2] Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IP, Dept Gastroenterol, Madrid, Spain

来源：

CURRENT DRUG METABOLISM | 2012年 / 13卷 / 09期

关键词：

CYP2C19; genetic polymorphism; Helicobacter pylori eradication; proton pump inhibitor; rabeprazole; omeprazole; lansoprazole; pantoprazole; esomeprazole; CYTOCHROME-P450; ENZYMES; 2C9; 1-WEEK TRIPLE THERAPY; RANDOMIZED OPEN TRIAL; ERADICATION RATE; CURE RATES; OMEPRAZOLE METABOLISM; GENOTYPIC DIFFERENCES; DRUG-METABOLISM; DUAL THERAPY; RABEPRAZOLE;

D O I：

10.2174/138920012803341393

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Proton pump inhibitors (PPIs) are the most potent acid suppressants available. PPIs undergo hepatic metabolism via the CYP2C system for the isoforms CYP2C19 and CYP3A4 in particular. Genetic polymorphisms in CYP2C19 may affect the metabolism of individual PPIs to different extents. Although PPIs are highly effective as a class, differences in their pharmacokinetics, such as bioavailability and metabolism, may translate into differences in clinical outcomes. In Helicobacter pylori infection, a significantly lower eradication rate was seen in extensive metabolizers with omeprazole but no with rabeprazole.

引用

页码：1303 / 1312

页数：10

共 104 条

[1]

Äbelö A, 2000, DRUG METAB DISPOS, V28, P966

[2] Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations [J].

Allabi, AC ;

Gala, JL ;

Desager, JP ;

Heusterspreute, M ;

Horsmans, Y .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (06) :653-657

[3] A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences [J].

Ando, T ;

Kato, H ;

Sugimoto, N ;

Nagao, Y ;

Seto, N ;

Hongo, H ;

Kajikawa, H ;

Isozaki, Y ;

Shimozawa, M ;

Naito, Y ;

Yoshida, N ;

Ishizaki, T ;

Yoshikawa, T .

DIGESTIVE DISEASES AND SCIENCES, 2005, 50 (09) :1625-1631

[4] Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population [J].

Aynacioglu, AS ;

Sachse, C ;

Bozkurt, A ;

Kortunay, S ;

Nacak, M ;

Schröder, T ;

Kayaalp, SO ;

Roots, I ;

Brockmöller, J .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (02) :185-192

[5] Increased omeprazole metabolism in carriers of the CYP2C19*17 allele;: a pharmacokinetic study in healthy volunteers [J].

Baldwin, R. Michael ;

Ohlsson, Staffan ;

Pedersen, Rasmus Steen ;

Mwinyi, Jessica ;

Ingelman-Sundberg, Magnus ;

Eliasson, Erik ;

Bertilsson, Leif .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 (05) :767-774

[6] Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity - Role of CYP2D6 and CYP2C19 in longevity [J].

Bathum, L ;

Andersen-Ranberg, K ;

Boldsen, J ;

Brosen, K ;

Jeune, B .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (05) :427-430

[7] Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population [J].

Bathum, L ;

Skjelbo, E ;

Mutabingwa, TK ;

Madsen, H ;

Horder, M ;

Brosen, K .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 48 (03) :395-401

[8]

Bozina N, 2003, CROAT MED J, V44, P425

[9] Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population:: an investigative and comparative study [J].

Bravo-Villalta, HV ;

Yamamoto, K ;

Nakamura, K ;

Bayá, A ;

Okada, Y ;

Horiuchi, R .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (03) :179-184

[10]

Buzoianu AD, 2010, FARMACIA, V58, P806

← 1 2 3 4 5 6 7 8 9 10 →